膀胱癌
单变量分析
比例危险模型
免疫疗法
肿瘤科
医学
危险系数
内科学
癌症
肿瘤微环境
循环肿瘤细胞
PD-L1
多元分析
癌症研究
转移
置信区间
作者
Maria Beatrice Morelli,Consuelo Amantini,J.A. Rossi De Vermandois,Marilena Gubbiotti,Antonella Giannantoni,Ettore Mearini,Federica Maggi,Massimo Nabissi,Oliviero Marinelli,Matteo Santoni,Alessia Cimadamore,Rodolfo Montironi,Giorgio Santoni
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2021-11-28
卷期号:13 (23): 5989-5989
被引量:19
标识
DOI:10.3390/cancers13235989
摘要
Background: PD-L1 represents a crucial immune checkpoint molecule in the tumor microenvironment, identified as a key target for cancer immunotherapy. A correlation between PD-L1 and EMT-related genes expression in various human cancers has been suggested. Methods: By ScreenCell filtration, digital droplet PCR and confocal microscopy analysis, we aimed to investigate the expression of PD-L1 and EMT/invasive genes (TWIST1, ZEB1, VIMENTIN, TIMP2) in circulating tumor cells (CTCs) collected from the blood of non-muscle-invasive bladder cancer (NMIBC) patients, assessing the prognostic value of these biomarkers in the disease. Welchs’ test and Mann–Whitney U test, correlation index, Kaplan–Meier, Univariate and Multivariate Cox hazard proportional analysis were used. Results: Higher PD-L1, TIMP2 and VIM mRNA levels were found in pT1 compared to pTa NMIBC. As evaluated by Kaplan–Meier and Univariate and Multivariate Cox analysis, enhancement of PD-L1, TWIST1 and TIMP2 expression reduces the recurrent free survival in NMIBC patients. Conclusions: High PD-L1, TWIST1 and TIMP2 mRNAs mark the recurrent-NMIBC patients and by reducing the RFS represent negative prognostic biomarkers in these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI